

1 **Association between aspirin dose and outcomes in patients with acute Kawasaki**  
2 **disease**

3 Takanori Suzuki, MD,<sup>1</sup> Nobuaki Michihata, MD, MPH, PhD,<sup>2</sup> Yohei Hashimoto, MD,  
4 PhD,<sup>3</sup> Tetsushi Yoshikawa, MD, PhD,<sup>1</sup> Kazuyoshi Saito, MD, PhD,<sup>1</sup> Hiroki Matsui,  
5 MPH,<sup>3</sup> Kiyohide Fushimi, MD, PhD,<sup>4</sup> Hideo Yasunaga, MD, PhD<sup>3</sup>

6 **Affiliations:** 1 Department of Pediatrics, Fujita Health University, Aichi, Japan

7 2 Department of Health Services Research, Graduate School of Medicine, The University  
8 of Tokyo, Tokyo, Japan

9 3 Department of Clinical Epidemiology and Health Economics, School of Public Health,  
10 The University of Tokyo, Tokyo, Japan

11 4 Department of Health Policy and Informatics, Tokyo Medical and Dental University  
12 Graduate School of Medicine, Tokyo, Japan

13 **Correspondence to:** Nobuaki Michihata, MD, MPH, PhD, Department of Health  
14 Services Research, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo,  
15 Bunkyo-ku, Tokyo 113-0033, Japan

16 E-mail: michihata@m.u-tokyo.ac.jp

17 Tel: +81-3-5841-1887

18 Fax: +81-3-5841-1888

19 Short title: Association between aspirin dose and KD outcomes

20 **Conflict of Interest Disclosures:** All authors have no potential conflicts of interest to  
21 disclose.

22

23 **Funding/Support:** This work was supported by grants from the Ministry of Health,  
24 Labour and Welfare, Japan (21AA2007 and 20AA2005), and the Ministry of  
25 Education, Culture, Sports, Science and Technology, Japan (20H03907).

26 All authors have no financial relationships relevant to this article to disclose.

27

28 **Open Access:** We do not want open access.

29

30 **Data sharing statement:** The datasets analyzed during the current study are not publicly  
31 available due to contracts with the hospitals providing data to the database.

32 **Abbreviations:** ADL: activities of daily living; CAA: coronary artery abnormalities; CI:  
33 confidence interval; ICD-10: International Classification of Diseases, Tenth Revision;  
34 IQR: interquartile range; IVIG: intravenous immunoglobulin, KD: Kawasaki Disease;  
35 SD: standard deviation; USD: United States Dollar

36

37

38 **Keywords:** Kawasaki disease, aspirin, coronary artery abnormalities, restricted cubic  
39 spline.

40 **Article Summary:** The study showed by restricted cubic spline that the dose of aspirin  
41 was no significant association between aspirin escalation and CAAs in patients with  
42 acute KD.

43 **What's Known on This Subject:** Aspirin is standard treatments used with IVIG of  
44 acute Kawasaki Disease (KD), Few studies have shown the most effective dosage of  
45 aspirin to to prevent CAAs.

46 **What This Study Adds:** The dose of aspirin was no significant association between  
47 aspirin escalation and CAAs in patients with acute KD.

48 **Total word count of the manuscript:** 2284 words

49

50 **Author contributions:**

51 Takanori Suzuki wrote the first draft of the manuscript. Nobuaki Michihata  
52 conceptualized and designed the study, drafted the initial manuscript, and reviewed and  
53 revised the manuscript. Kazuyoshi Saito, Tetsushi Yoshikawa, Hiroki Matsui, Kiyohide  
54 Fushimi, and Hideo Yasunaga conceptualized and designed the study, and coordinated  
55 and critically reviewed the manuscript for important intellectual content. All authors  
56 approved the final manuscript as submitted and agree to be accountable for all aspects of  
57 the work.

58

59 .



61 **Abstract**

62 **Background:** The most effective dosage of aspirin to prevent coronary artery  
63 abnormalities in patients with acute Kawasaki disease remains unknown. Using a  
64 Japanese national inpatient database, this study aimed to identify the appropriate dose of  
65 aspirin to be prescribed to patients with acute Kawasaki disease.

66 **Method:** We used the Diagnostic Procedure Combination database to identify patients  
67 with Kawasaki disease treated with intravenous immunoglobulin between 2010 and  
68 2021. The outcomes included the occurrence of coronary artery abnormalities and  
69 intravenous immunoglobulin resistance, length of stay, and medical costs. Restricted  
70 cubic spline functions were performed to examine the association between aspirin dose  
71 and the outcomes.

72 **Results:** Data of 82109 patients were extracted from the database. Non-linear  
73 associations were observed between aspirin dose and the outcomes. In comparison with  
74 an aspirin dose of 30 mg/kg/day, the odds ratio (95% confidence interval) for coronary  
75 artery abnormalities was 1.40 (1.13–1.75) at 5 mg/kg/day. An aspirin dose of  $\geq 30$   
76 mg/kg/day did not significantly change the odds ratio for coronary artery abnormalities.  
77 Compared with a dose of 30 mg/kg/day, the odds ratio (95% confidence interval) for  
78 intravenous immunoglobulin resistance was 0.87 (0.76–1.00) at 5 mg/kg/day and 0.59  
79 (0.36–0.98) at 80 mg/kg/day. An increase in aspirin dose was associated with a shorter  
80 length of stay and lower medical costs.

81 **Conclusions:** Low-dose aspirin may increase the risk of coronary artery abnormalities in  
82 patients with acute Kawasaki disease; however, increasing aspirin doses beyond the  
83 standard doses may not be associated with a reduction in coronary artery abnormalities.  
84 High-dose aspirin showed the potential to reduce hospital stay and medical costs without  
85 increasing complications.

86

87

88 **Introduction**

89 Kawasaki disease (KD) represents an acute form of systemic vasculitis, which most  
90 commonly leads to acquired heart disease in children in most industrialized countries.<sup>1</sup>  
91 The standard treatment for patients with acute KD is the administration of aspirin and  
92 intravenous immunoglobulin (IVIG). As for the aspirin dose for patients with acute KD,  
93 the American Heart Association guidelines for KD recommend 80–100 mg/kg/day, while  
94 the Japanese Society of Pediatric Cardiology and Cardiac Surgery guidelines for KD  
95 recommend 30–50 mg/kg/day in the acute KD.<sup>2,3</sup> However, various trials have  
96 investigated the effectiveness of different aspirin doses for patients with acute KD.  
97 Recent small-scale studies have reported no difference in coronary artery abnormalities  
98 (CAAs) outcomes with aspirin doses as low as 3–5 mg/kg/day or as high as 100  
99 mg/kg/day.<sup>4-9</sup> Another study found that high doses of aspirin enhanced the production of  
100 tumor necrosis factor-alpha (TNF- $\alpha$ ), which is related to the development of CAAs.<sup>11</sup>  
101 Thus, the results of previous studies are controversial, and the most appropriate dose of  
102 aspirin remains unknown. Conversely, it was recently reported that high-dose aspirin may  
103 have a negative effect on the initial IVIG therapy during the acute febrile phase of KD.<sup>10</sup>  
104 This study aimed to examine the association between aspirin dose and outcomes in  
105 patients with acute KD, using a Japanese national inpatient database.

106 **Methods**

107 Data source

108 For this retrospective cohort study, we used data from the Diagnosis Procedure  
109 Combination database. Over 80 academic hospitals are obliged to participate in the  
110 database; however, the participation of community hospitals in the database is voluntary.  
111 Data for about 8 million hospitalized patients of all ages are included every year. It is  
112 almost equivalent to 50% of the total acute-care hospitalizations in Japan. The database  
113 includes the following information: unique identifiers of hospitals, patient baseline  
114 characteristics, and diagnosis at admission, comorbidities at admission, and  
115 complications after admission recorded with text data in Japanese and International  
116 Classification of Diseases, Tenth Revision (ICD-10) codes; medical procedures and  
117 treatments, including drug administrations, devices use, and surgical and nonsurgical  
118 procedures, length of stay, discharge status, and medical cost during hospitalization.  
119 Attending physicians must record diagnoses and comorbidities with reference to medical  
120 records. The current study was approved by the Institutional Review Board of The  
121 University of Tokyo (approval number: 3501-(5) (May 19th, 2021). The requirement for  
122 informed consent was waived due to the anonymous nature of the data.

123

124 Participants

125 We identified patients diagnosed with KD (ICD-10 code: M303) between July 2010 and  
126 March 2021. We included patients who were treated with initial IVIG treatment. We  
127 further checked the Japanese text describing the detailed diagnoses in each case to include  
128 patients with atypical KD and exclude patients with a ‘suspected’ diagnosis of KD. We  
129 excluded patients who weighed <3 kg, >60 kg or had missing data. Patients who used  
130 flurbiprofen were excluded from our study. The initial aspirin dose was defined as the  
131 dose used at the same time as the initial IVIG in the acute phase of KD. We also excluded  
132 initial aspirin dose <3 mg/kg/day or initial aspirin dose >90 mg/kg/day. We classified the  
133 study population according to the aspirin dose at the initial treatment of IVIG: low-dose  
134 group, aspirin <30 mg/kg/day; standard-dose group, 30–50 mg/kg/day; and high-dose  
135 group, >50 mg/kg/day.

136 Outcomes

137 The primary outcome was the occurrence of CAAs upon discharge. CAAs were identified  
138 with a recorded diagnosis of CAAs (ICD-10 code: I25.4) and/or text data of CAAs in the  
139 Japanese language. The secondary outcomes were IVIG resistance, length of stay,

140 medical costs, and adverse events. We converted 1 United States dollar (USD) to 100  
141 Japanese yen. IVIG resistance was defined as the use of IVIG at a total dose of  $\geq 4.0$  g/kg  
142 and/or a combination of any steroid, infliximab, cyclosporine, and/or plasma exchange  
143 that was not administered during the initial IVIG treatment. The medical costs included  
144 costs of surgery, drugs, laboratory tests, and other inpatient services, including food  
145 expenses. We also examined adverse events after admission occurring with aspirin,  
146 including Reye syndrome (ICD-10 code: G937), bleeding from the upper gastrointestinal  
147 tract (ICD-10 code: K922), anemia (ICD-10 code: D5, D60-4), gastric ulcer (ICD-10  
148 code: K25-6), and liver function abnormality (ICD-10 code: K719, K769) /or text data of  
149 adverse events in the Japanese language.

#### 150 Covariates

151 The baseline characteristics included sex, age, weight, height, hospital days of illness at  
152 initial IVIG, use of 10% IVIG, initial steroid use, initial cyclosporine use, type of hospital,  
153 complex chronic conditions,<sup>12</sup> Japan Coma Scale at admission, transportation by  
154 ambulance, transportation from other hospitals, and hospital volume. Initial steroid use  
155 and initial cyclosporine use were defined as those concurrent with initial IVIG use. For  
156 the hospital type, academic hospitals were defined as university hospitals and related



157 hospitals. The Japan Coma Scale score at admission was categorized into two groups:  
158 alert and not alert. Japan Coma Scale assessment was previously clarified to be well  
159 associated with the Glasgow Coma Scale assessment.<sup>13</sup> Hospital volume was defined as  
160 the number of all patients with KD at each hospital every year. Hospital volume was  
161 divided into tertiles so that the number of patients in each group was almost equal.

#### 162 Statistical analysis

163 Categorical variables were presented as numbers and percentages and were compared  
164 using the Fisher exact test. Continuous variables were presented as means and standard  
165 deviations (SD) or medians and interquartile ranges (IQR). Non-normally distributed  
166 variables (length of stay and medical costs) were compared among the three groups using  
167 the Kruskal–Wallis test. The sensitivity analysis of CAAs was limited to those who had a  
168 diagnosis of CAAs and were using anticoagulants, such as warfarin or clopidogrel, or  
169 were undergoing cardiac catheterization.

#### 170 Restricted cubic spline functions

171 Studies regarding the relationship between aspirin dose and outcomes converted  
172 continuous measures of aspirin into categorical variables. However, this may have  
173 resulted in a loss of information and a decrease in statistical power.<sup>14</sup> Therefore, we used

174 multivariable regression models with restricted cubic spline functions to assess the  
175 potential non-linear association of aspirin dose with CAAs, IVIG resistance, length of  
176 stay, and medical cost. Multivariable logistic regression models were applied for the  
177 occurrence of CAAs and IVIG resistance, and multiple regression models were applied  
178 for length of stay and medical cost with adjustment for age, sex, body weight, body height,  
179 hospital days of illness at the initial IVIG treatment, use of 10% IVIG, initial steroid use,  
180 initial cyclosporine use, type of hospital, complex chronic conditions, transportation by  
181 ambulance, Japan Coma Scale at admission, transportation from another hospital, fiscal  
182 year, and hospital volume. We created restricted cubic splines with five knots at  
183 pre-specified locations according to the percentiles of the distribution of aspirin doses (10,  
184 30, 40, 50, and 70 mg/kg/day). Tests for overall and non-linear associations were  
185 performed using the  $\chi^2$  test.<sup>15</sup> A two-sided value of  $P < .05$  was considered significant.  
186 Statistical analyses were performed using the Stata software 17 (StataCorp LP, TX,  
187 USA).

188

189

190

191 **Results**

192 Patient characteristics are shown in Table 1. Initially, 82,109 patients with acute KD were  
193 identified using the inclusion criteria (Figure 1). The mean age was 2.1 years (SD, 2.0),  
194 and the mean body weight was 12.3 kg (SD, 4.7). Of them, 47,277 (57.6%) were male.  
195 The median total amount of aspirin was 30.1 mg/kg/day (IQR, 29.4–32.3). Regarding the  
196 aspirin dose, the low-dose group (n=30,439) had a median of 28.9 mg/kg/day (IQR, 27.5–  
197 29.5), the standard-dose group (n=49,646) had a median of 31.1 mg/kg/day (IQR, 30.2–  
198 36.4), and the high-dose group (n=2,024) had a median of 52.1 mg/kg/day (IQR, 50.8–  
199 58.5) ( $P<.001$ ). Moreover, the high-dose group was associated with younger age, smaller  
200 weight, lower height, longer hospital days of illness, 10% IVIG and initial steroid, initial  
201 cyclosporine, academic hospital, the score of complex chronic conditions, and transport  
202 ambulance. CAAs and IVIG resistance occurred in 1817 (2.2%) and 15717 (19.1%)  
203 patients, respectively. The median (IQR) of length of stay and medical costs was 10 days  
204 (8.0–12.0) and 6454 USD (5299–8169), respectively.

205 Compared with the low- and high-dose groups, the standard-dose group showed lower  
206 proportions of CAAs (2.0%,  $P<.001$ ), shorter length of stay (median, 10 days;  $P<.001$ ),  
207 and lower medical costs (median, 6440 USD;  $P<.001$ ) (Table 2).

208 No patients had Reye syndrome. There were no significant differences between the  
209 groups in the proportion of other adverse events (bleeding from the upper gastrointestinal  
210 tract, anemia, gastric ulcer, and liver function abnormality) (Table 1).

211 In the sensitivity analysis, CAAs were confirmed in 527 patients (0.6%) among the study  
212 participants. Similar to the main analysis, the standard dose group showed the lowest  
213 proportion of CAAs (0.6%,  $P<.001$ ).

214 Regarding restricted cubic spline functions, tests for overall association and non-linear  
215 association showed significant non-linear relationships between aspirin dose and the  
216 outcomes. In comparison with an aspirin dose of 30 mg/kg/day, the odds ratio (95%  
217 confidence interval [CI]) for CAA was 1.40 (1.13–1.75) at 5 mg/kg/day. For aspirin doses  
218 of 30 mg/kg/day or higher, the 95% CIs for the occurrence of CAA were almost across 1  
219 and not significantly different when compared with the values observed at 30 mg/kg/day  
220 (Figure 2).

221 The odds ratio (95% CI) for IVIG resistance was 0.87 (0.76–1.0) at the aspirin dose of 5  
222 mg/kg/day and 0.59 (0.36–0.98) at 80 mg/kg/day when compared with 30 mg/kg/day  
223 (Figure 3). The difference (95% CI) in the length of stay was 0.33 (0.15–0.5) days at 5  
224 mg/kg/day and 2.32 (1.61–3.03) days at 80 mg/kg/day with reference to 30 mg/kg/day

225 (Figure 4). The difference in medical costs was 55.8 (42.8–154.4) USD at 5 mg/kg/day  
226 and -2,307 (-2,707--1, 907) USD at 80 mg/kg/day when compared with the values  
227 observed at 30 mg/kg/day (Figure 5).

228 In the sensitivity analysis for CAA, the odds ratio (95% CI) for CAA was 1.86 (1.33–  
229 2.59) at 5 mg/kg/day compared with the values observed at 30 mg/kg/day. For aspirin  
230 doses of 30 mg/kg/day or higher, the 95% CIs for CAA were across 1 and not  
231 significantly different when compared with the values observed at 30 mg/kg/day (Figure  
232 6).

233

234

235

236

237

238 **Discussion**

239 Our study evaluated serial aspirin doses from low (3 mg/kg/day) to high doses (90  
240 mg/kg/day). Aspirin was generally considered to have antiplatelet effects at low doses  
241 and anti-inflammatory effects at standard or high doses. In this study, we examined a  
242 larger number of patients than those in previous studies and found that low-dose aspirin  
243 was significantly associated with a higher proportion of CAA. We also found that  
244 standard and high doses (over 50 mg/kg/day) of aspirin did not significantly change the  
245 occurrence of CAA.

246 The results of previous studies were inconsistent regarding the association between  
247 aspirin dose and CAA occurrence.<sup>6,10,11,16</sup> Our results suggest that at least an  
248 anti-inflammatory dose of aspirin may be needed to reduce inflammation and prevent  
249 CAA in KD, and aspirin above the anti-inflammatory dose may neither suppress nor  
250 enhance the inflammatory response of patients with acute KD. Since these mechanisms  
251 are unknown, further basic research on KD is required to elucidate these mechanisms.

252 We showed that the low-dose and high-dose aspirin (>50 mg/kg/day) was associated with  
253 less proportion of IVIG resistance in patients with acute KD. Some previous reports  
254 indicated that lower aspirin doses may increase IVIG resistance,<sup>7,8,16</sup> while others showed

255 no significant difference in aspirin dose for IVIG resistance.<sup>4-6,9</sup> The reason is unknown;  
256 however, clinicians may use low-dose aspirin in mild cases of patients with acute KD.

257 The present study showed that the use of high-dose aspirin (over 50 mg/kg/day) was  
258 associated with a shorter length of hospital stay and lower medical costs. Previous studies  
259 reported similar results for length of stay due to faster resolution of fever.<sup>17,18</sup> Considering  
260 the results for length of stay and medical costs, the use of high-dose aspirin (over 50  
261 mg/kg/day) may have resulted in early discharge from the hospital due to early resolution  
262 of fever, thus resulting in lower medical costs.

263 The present study examined possible adverse effects of aspirin and found no association  
264 between aspirin dose and adverse effects. A previous study showed anemia after IVIG  
265 treatment in patients who received over 30 mg/kg/day of aspirin.<sup>5</sup> Another study showed  
266 gastrointestinal hemorrhage related to high-dose aspirin over 70 mg/kg/day.<sup>19</sup> Many  
267 previous studies reported liver dysfunction due to KD inflammation, while liver  
268 dysfunction due to Reye's syndrome was shown in patients with aspirin doses of 100  
269 mg/kg/day.<sup>20,21</sup> In our study, no cases of Reye syndrome were encountered. In general,  
270 side effects are often dose-dependent; but in this study, the proportion of side effects in  
271 the high-dose group (over 50 mg/kg/day) was not high.

272 Limitations

273 We acknowledge several limitations in this study. First, our database lacked data  
274 regarding KD symptoms, laboratory findings, and fever duration of patients with acute  
275 KD. It is impossible to know from our database the days of illness during admission of the  
276 patient to the hospital. Therefore, we considered the days of hospital stay as days of  
277 illness. Patients who received steroids or cyclosporine are likely to have a higher severity  
278 of KD as per the Japanese Kawasaki disease score for severity classification.<sup>22,23</sup> Second,  
279 the severity of CAAs due to KD, which was expressed as coronary arterial diameters or Z  
280 scores, was not included in our database. To clarify that CAAs were not transient, we used  
281 the history of cardiac catheterization and the prescription history of anticoagulants in  
282 addition to aspirin for sensitivity analysis. Third, adverse events due to aspirin were  
283 identified with recorded diagnoses, but these may have been underreported. Fourth, a few  
284 patients in our database used aspirin at doses greater than 90 mg/kg/day. Finally, because  
285 most of the patients in this study were Japanese and the generalizability of the present  
286 results to other populations may be limited.

287 **Conclusion**



288 The results showed no significant association between aspirin escalation and CAAs in  
289 patients with acute KD. High-dose aspirin showed the potential to reduce hospital stay  
290 and medical costs without increasing complications.

291 **Acknowledgements**

292 **Funding Source:** This work was supported by grants from the Ministry of Health,  
293 Labour and Welfare, Japan (21AA2007 and 22AA2003) and the Ministry of Education,  
294 Culture, Sports, Science and Technology, Japan (20H03907).

295 **Financial Disclosure:** None of the authors have any financial relationships relevant to  
296 this article to disclose.

297 **Conflict of Interest:** None of the authors have any potential conflict of interest to  
298 disclose.

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316 **References**

- 317 1. Newburger JW, Takahashi M, Burns JC. Kawasaki disease. *J Am Coll Cardiol.*  
318 2016;67(14):1738-1749.
- 319 2. Mccrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term  
320 management of Kawasaki disease: A scientific statement for health professionals from  
321 the American Heart Association. *Circulation.* 2017;135(17):e927-e999.
- 322 3. Miura M, Ayusawa M, Ito S. The guidelines on acute stage Kawasaki disease treatment.  
323 *Pediatr Cardiol Card Surg.* 2020;36(suppl 1):S1.1-S1.29.
- 324 4. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute  
325 Kawasaki disease: aspirin's role in the febrile stage revisited. *Pediatrics.*  
326 2004;114(6):e689-e693.
- 327 5. Kuo HC, Lo MH, Hsieh KS, Guo MMH, Huang YH. High-dose aspirin is associated  
328 with anemia and does not confer benefit to disease outcomes in Kawasaki disease. *PLOS*  
329 *ONE*, Woo PC, ed. 2015;10(12):e0144603.
- 330 6. Dallaire F, Fortier-Morissette Z, Blais S, et al. Aspirin dose and prevention of coronary  
331 abnormalities in Kawasaki disease. *Pediatrics.* 2017;139(6):e20170098.
- 332 7. Kim GB, Yu JJ, Yoon KL, et al. Medium- or higher-dose acetylsalicylic acid for acute  
333 Kawasaki disease and patient outcomes. *J Pediatr.* 2017;184:125-129.e1.
- 334 8. Zheng X, Yue P, Liu L, et al. Efficacy between low and high dose aspirin for the initial  
335 treatment of Kawasaki disease: current evidence based on a meta-analysis, editor. *PLOS*  
336 *ONE.* 2019;14(5):e0217274.
- 337 9. Jia X, Du X, Bie S, Li X, Bao Y, Jiang M. What dose of aspirin should be used in the  
338 initial treatment of Kawasaki disease? A meta-analysis. *Rheumatology (Oxford).*  
339 2020;59(8):1826-1833.
- 340 10. Simon TD, Berry J, Feudtner C, et al. Children with complex chronic conditions in  
341 inpatient hospital settings in the United States. *Pediatrics.* 2010;126(4):647-655.
- 342 11. Yumoto T, Naito H, Yorifuji T, Aokage T, Fujisaki N, Nakao A. Association of Japan  
343 Coma Scale score on hospital arrival with in-hospital mortality among trauma patients.  
344 *BMC Emerg Med.* 2019;19(1):65.

- 345 12. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in  
346 multiple regression: a bad idea. *Stat Med.* 2006;25(1):127-141.
- 347 13. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline  
348 functions in public health research. *Stat Med.* 2010;29(9):1037-1057.
- 349 14. Ito Y, Matsui T, Abe K, et al. Aspirin dose and treatment outcomes in Kawasaki  
350 disease: A historical control study in Japan. *Front Pediatr.* 2020;8:249.
- 351 15. Nakada T. Effects of anti-inflammatory drugs on intravenous immunoglobulin  
352 therapy in the acute phase of Kawasaki disease. *Pediatr Cardiol.* 2015;36(2):335-339.
- 353 16. Lau AC, Duong TT, Ito S, Yeung RSM. Intravenous immunoglobulin and salicylate  
354 differentially modulate pathogenic processes leading to vascular damage in a model of  
355 Kawasaki disease. *Arthritis Rheum.* 2009;60(7):2131-2141.
- 356 17. Akagi T, Kato H, Inoue O, Sato N. A study on the optimal dose of aspirin therapy in  
357 Kawasaki disease—clinical evaluation and arachidonic acid metabolism. *Kurume Med J.*  
358 1990;37(3):203-208.
- 359 18. Lee G, Lee SE, Hong YM, Sohn S. Is high-dose aspirin necessary in the acute phase  
360 of Kawasaki disease? *Korean Circ J.* 2013;43(3):182-186.
- 361 19. Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal  
362 hemorrhage complicating aspirin therapy in acute Kawasaki disease. *J Pediatr.*  
363 1996;128(5 Pt 1):701-703.
- 364 20. Wei CM, Chen HL, Lee PI, Chen CM, Ma CY, Hwu WL. Reye's syndrome  
365 developing in an infant on treatment of Kawasaki syndrome. *J Paediatr Child Health.*  
366 2005;41(5-6):303-304.
- 367 21. Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of one  
368 case. *Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi.* 1992;33(1):67-71.
- 369 22. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for  
370 prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a  
371 randomised, open-label, blinded-endpoints trial. *Lancet.* 2012;379(9826):1613-1620.
- 372 23. Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with  
373 immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in

374 patients with Kawasaki disease predicted to be at increased risk of non-response to  
375 intravenous immunoglobulin (KAICA): a randomised controlled, open-label,  
376 blinded-endpoints, phase 3 trial. *Lancet*. 2019;393(10176):1128-1137.

377

378

379

380

381

382

383

Table 1. Patients Characteristics

Variables	Total (N = 82109)	Low-dose group (N = 30349)	Standard-dose group (N=49646)	High-dose group (N=2024)	P value
Age (years), mean (SD)	2.1 (2.0)	2.2 (2.1)	2.1 (2.0)	2.1 (2.1)	<.001
Male (%)	47277 (57.6%)	17553 (57.7%)	28561 (57.5%)	1163 (57.5%)	.92
Weight (kg), mean (SD)	12.3 (4.7)	12.5 (5.0)	12.1 (4.4)	11.2 (4.8)	<.001
Height (cm), mean (SD)	77.5 (32.0)	78.4 (30.8)	76.9 (32.8)	76.4 (29.2)	<.001
Hospital days of illness at initial IVIG, median (IQR)	2 (1.0-2.0)	2 (1.0-2.0)	2 (1.0-2.0)	2 (1.0-3.0)	.002
Total amount of initial aspirin (mg/kg/day), median (IQR)	30.1 (29.4-32.3)	28.9 (27.5-29.5)	31.1 (30.2-36.4)	52.1 (50.8-58.5)	<.001
Use of 10% IVIG	9266 (11.5%)	3351 (11.2%)	5626 (11.5%)	289 (14.5%)	<.001
Initial steroid use	8451 (10.3%)	3445 (11.3%)	4830 (9.7%)	176 (8.7%)	<.001
Initial cyclosporine use	233 (0.3%)	99 (0.3%)	120 (0.2%)	14 (0.7%)	<.001
Adverse event after admission					
Reye syndrome	0	0	0	0	
Bleeding from the upper gastrointestinal tract	340 (0.4%)	135 (0.4%)	200 (0.4%)	5 (0.2%)	.34
Anemia	735 (0.9%)	278 (0.9%)	432 (0.9%)	25 (1.2%)	.21
Gastric ulcer	762 (0.9%)	281 (0.9%)	463 (0.9%)	18 (0.9%)	.97
Liver function abnormality	216 (0.3%)	78 (0.3%)	135 (0.3%)	3 (0.1%)	.54
Type of hospital					<.001
Academic hospital	15092 (20.6%)	6111 (22.2%)	8405 (19.1%)	576 (32.3%)	
Complex Chronic Conditions					
0-1	78846 (96.0%)	29201 (95.9%)	47722 (96.1%)	1923 (95.0%)	.024
2 ≤	3263 (4.0%)	1238 (4.1%)	1924 (3.9%)	101 (5.0%)	
Transportation by ambulance	1928 (2.3%)	758 (2.5%)	1100 (2.2%)	70 (3.5%)	<.001
Japan coma scale at admission					.464
Alert	81454 (99.2%)	30181 (99.2%)	49265 (99.2%)	2008 (99.2%)	
Not Alert	655 (0.8%)	258 (0.8%)	381 (0.8%)	16 (0.8%)	
Transported from another hospital	63212 (77.0%)	23869 (78.4%)	37865 (76.3%)	1478 (73.0%)	<.001
Hospital volume					
Low (1-29.0)	25255 (30.8%)	8876 (29.2%)	15871 (32.0%)	508 (25.1%)	<.001
Middle (29.0-53.5)	28233 (34.4%)	10678 (35.1%)	16971 (34.2%)	584 (28.9%)	
High (≥ 53.6)	28621 (34.9%)	10885 (35.8%)	16804 (33.8%)	932 (46.0%)	

IQR: interquartile range; IVIG: intravenous immunoglobulin; SD: standard deviation

Table 2. Comparison of outcomes among the three groups with different doses of Aspirin

Variables	Total (N =82109)	Low-dose group (N =30439)	Standard-dose group (N=49646)	High-dose group (N=2024)	<i>P</i> value
Proportion of CAAs (%)	1817 (2.2%)	741 (2.4%)	1014 (2.0%)	62 (3.1%)	<.001
Proportion of IVIG resistance (%)	15717 (19.1%)	5403 (17.8%)	9765 (19.7%)	549 (27.1%)	<.001
Length of stay (day)	10.0 (8.0-12.0)	10.0 (8.0-12.0)	10.0 (8.0-12.0)	10.0 (8.0-13.0)	<.001
Medical cost (USD)	6454 (5299-8169)	6461 (5299-8184)	6440 (5292-8139)	6806 (5470-8895)	<.001
Proportion of CAAs (sensitivity analysis **) (%)	527 (0.6%)	227 (0.7%)	281 (0.6%)	19 (0.9%)	.002

CAAs: coronary artery abnormalities; IVIG: intravenous immunoglobulin; USD: United States dollars

\* All data are presented as medians (interquartile ranges).

\*\* CAA in the sensitivity analysis was defined as a diagnosis of CAA (the main analysis was diagnosis only) and drug therapy (warfarin or clopidogrel) and/or cardiac catheterization.

## Figure legends

Figure 1. Flow chart for the study cohort

ICD-10: International Classification of Diseases, Tenth Revision; IVIG: intravenous immunoglobulin; KD: Kawasaki disease

Figure 2. Restricted cubic spline for coronary artery abnormalities

The dose–response relationship between aspirin dose and proportion of coronary artery abnormalities was adjusted by analysis using a restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50, and 70 mg/kg/day). The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval

Figure 3. Restricted cubic spline for intravenous immunoglobulin resistance



The dose–response relationship between aspirin dose and proportion of intravenous immunoglobulin resistance was adjusted by analysis using a restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50, and 70 mg/kg/day). The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval

Figure 4. Restricted cubic spline for length of hospital stay

The dose–response relationship between aspirin dose and the length of hospital stay was adjusted by analysis using a restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50, and 70 mg/kg/day). The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval

Figure 5. Restricted cubic spline for total medical cost

The dose–response relationship between aspirin dose and the total medical cost was adjusted by analysis using a restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50, and 70 mg/kg/day) The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval

Figure 6. Restricted cubic spline for coronary artery abnormalities in the sensitivity analysis

The dose–response relationship between aspirin dose and proportion of coronary artery abnormalities in the sensitivity analysis (limited to those with anticoagulant use or cardiac catheterization as well as diagnosis of coronary artery abnormalities) was adjusted by analysis using a restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50 and 70 mg/kg/day). The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval











